Research Analysts Offer Predictions for ALNY Q1 Earnings

1 day ago · Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) – Equities research analysts at Zacks Research upped their Q1 2026 earnings per share (EPS) estimates for …

CouponFollow Extension

$2.21
OFF

FY2024 Earnings Estimate For ALNY Issued By Zacks Research

3 weeks from now

Jan 17, 2025 · The consensus estimate for Alnylam Pharmaceuticals' current full-year earnings is ($2.21) per share. Zacks Research also issued estimates for Alnylam Pharmaceuticals' Q4 …

marketbeat.com

$3.16
OFF

Research Analysts Offer Predictions For ALNY FY2024 Earnings

3 weeks from now

Jan 19, 2025 · Read Research Analysts Offer Predictions for ALNY FY2024 Earnings at ETF Daily News ... EPS, FY2025 earnings at ($3.16) EPS, Q1 2026 earnings at $0.34 EPS, Q2 …

etfdailynews.com

$0.51
OFF

Alnylam Pharmaceuticals (ALNY) Earnings Date And Reports 2025

3 weeks from now

4 days ago · In the previous quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) missed the analysts' consensus estimate of ($0.51) by $0.36 with a reported earnings per share (EPS) of …

marketbeat.com

$118.55
OFF

Compared To Estimates, Alnylam (ALNY) Q1 Earnings: A Look At …

3 weeks from now

May 2, 2024 · Net revenues from research collaborators: $118.55 million versus $58.26 million estimated by seven analysts on average. Compared to the year-ago quarter, this number …

yahoo.com

5%
OFF

Gear Up For Alnylam (ALNY) Q1 Earnings: Wall Street Estimates For …

3 weeks from now

Apr 30, 2024 · The average prediction of analysts places 'Product revenues, net' at $344.00 million. The estimate indicates a year-over-year change of +24.5%. Analysts' assessment …

yahoo.com

$305.00
OFF

What Is William Blair’s Forecast For ALNY FY2024 Earnings?

3 weeks from now

Jan 17, 2025 · Other equities analysts also recently issued research reports about the company. Scotiabank lifted their price objective on Alnylam Pharmaceuticals from $305.00 to $310.00 …

etfdailynews.com

$2.00
OFF

Alnylam (ALNY) Misses On Q1 Earnings, Lowers '22 Revenue View

3 weeks from now

Apr 29, 2022 · Alnylam Pharmaceuticals, Inc. ALNY incurred a loss of $2.00 per share in the first quarter of 2022, wider than the Zacks Consensus Estimate of a loss of $1.93.The loss …

yahoo.com

30%
OFF

Prediction: Palantir Will Beat Wall Street's Earnings And Revenue ...

3 weeks from now

4 days ago · On the earnings side, it exceeded Wall Street's expectation in Q2 and Q3 and met the expectation in Q1. Q3 2024 : Revenue grew 30% year over year, beating the 26% Wall …

fool.com

$0.51
OFF

Seeking Clues To Alnylam (ALNY) Q3 Earnings? A Peek Into Wall …

3 weeks from now

Oct 28, 2024 · Analysts on Wall Street project that Alnylam Pharmaceuticals (ALNY) will announce quarterly loss of $0.51 per share in its forthcoming report, representing a decline of …

yahoo.com

FAQs about Research Analysts Offer Predictions for ALNY Q1 Earnings Coupon?

Is Alnylam a good stock to buy now?

For Alnylam, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -13.38%. On the other hand, the stock currently carries a Zacks Rank of #3. ...

How did Alnylam perform in the just reported quarter?

Here is how Alnylam performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Product revenues, net: $365.16 million versus the eight-analyst average estimate of $344 million. The reported number represents a year-over-year change of +32.2%. ...

Should investors rely on analysts' forecasts for key metrics?

While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights. ...

How much did CMO Pushkal Garg sell Alnylam Pharmaceuticals stock?

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36. ...

Who owns Alnylam Pharmaceuticals?

Jennison Associates LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at approximately $61,160,000. Strategic Financial Concepts LLC acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at approximately $41,529,000. ...

What does Alnylam Pharmaceuticals do?

(Get Free Report) Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. ...